GSA Capital Partners’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $556K | Buy |
492,121
+8,353
| +2% | +$9.44K | 0.04% | 853 |
|
|
2025
Q1 | $706K | Buy |
+483,768
| New | +$706K | 0.06% | 562 |
|
|
2024
Q3 | – | Sell |
-835,342
| Closed | -$1.95M | – | 1565 |
|
|
2024
Q2 | $1.95M | Buy |
+835,342
| New | +$1.95M | 0.14% | 159 |
|
|
2024
Q1 | – | Sell |
-20,518
| Closed | -$66K | – | 1573 |
|
|
2023
Q4 | $66K | Sell |
20,518
-106,294
| -84% | -$342K | 0.01% | 1413 |
|
|
2023
Q3 | $402K | Buy |
+126,812
| New | +$402K | 0.03% | 922 |
|
|
2023
Q1 | – | Sell |
-251,384
| Closed | -$1.58M | – | 1449 |
|
|
2022
Q4 | $1.58M | Buy |
251,384
+219,538
| +689% | +$1.38M | 0.2% | 53 |
|
|
2022
Q3 | $344K | Buy |
+31,846
| New | +$344K | 0.05% | 832 |
|
|
2022
Q2 | – | Sell |
-148,804
| Closed | -$1.36M | – | 1364 |
|
|
2022
Q1 | $1.36M | Buy |
148,804
+33,989
| +30% | +$310K | 0.18% | 83 |
|
|
2021
Q4 | $1.71M | Buy |
+114,815
| New | +$1.71M | 0.22% | 46 |
|
|
2021
Q3 | – | Sell |
-13,951
| Closed | -$364K | – | 1386 |
|
|
2021
Q2 | $364K | Buy |
+13,951
| New | +$364K | 0.04% | 817 |
|
|
2021
Q1 | – | Sell |
-11,273
| Closed | -$285K | – | 1070 |
|
|
2020
Q4 | $285K | Buy |
+11,273
| New | +$285K | 0.05% | 767 |
|
|
2020
Q1 | – | Sell |
-10,622
| Closed | -$276K | – | 1025 |
|
|
2019
Q4 | $276K | Buy |
+10,622
| New | +$276K | 0.03% | 1079 |
|